Base de dados : MEDLINE
Pesquisa : E02.190.755 [Categoria DeCS]
Referências encontradas : 35275 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3528 ir para página                         

  1 / 35275 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505506
[Au] Autor:Payab M; Hasani-Ranjbar S; Aletaha A; Ghasemi N; Qorbani M; Atlasi R; Abdollahi M; Larijani B
[Ad] Endereço:Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute.
[Ti] Título:Efficacy, safety, and mechanisms of herbal medicines used in the treatment of obesity: A protocol for systematic review.
[So] Source:Medicine (Baltimore);97(1):e8825, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: This systematic review protocol aims to perform a protocol for assessing the effectiveness, safety, and mechanism of herbal medicines for the treatment of obesity and metabolic syndrome. Some systematic reviews conducted earlier have evaluated the efficacy of herbal medicine to treat obesity and metabolic syndrome. Owing to the huge burden imposed by obesity in the recent years, a need is felt for conducting new systematic reviews on the topic of obesity with a focus on randomized clinical trials, we felt the need. METHODS AND ANALYSIS: All relevant clinical trials that examine the effectiveness of herbal medicines for the treatment of obesity and metabolic syndrome without restrictions on publication status will be applied.Four electronic databases will be searched: PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials. The main outcome is expected to be an improvement in the body weight, body mass index, waist circumference, waist-to-hip ratio, body fat (weight or mass of visceral adipose tissue, fat mass or percent), and appetite.Selection studies, data extraction, and risk of bias will be assessed independently by 2 authors. ETHICS AND DISSEMINATION: In this study, ethical approval is not required because the data that will be used are not subjects and the results will be discussed through peer-reviewed publications. TRIAL REGISTRATION NUMBER: PROSPEROCRD42016049753.
[Mh] Termos MeSH primário: Obesidade/tratamento farmacológico
Fitoterapia
Extratos Vegetais/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Plant Extracts)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008825


  2 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29367486
[Au] Autor:Miyazawa N; Yoshimoto H; Kurihara S; Hamaya T; Eguchi F
[Ad] Endereço:Faculty of Regional Environment Science, Tokyo University of Agriculture.
[Ti] Título:Improvement of Diet-induced Obesity by Ingestion of Mushroom Chitosan Prepared from Flammulina velutipes.
[So] Source:J Oleo Sci;67(2):245-254, 2018 Feb 01.
[Is] ISSN:1347-3352
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The anti-obesity effects of mushroom chitosan prepared from Flammulina velutipes were investigated using an animal model with diet-induced obesity. In this study, 5-week-old imprinting control region (ICR) mice were divided into six groups of 10 mice each and fed different diets based on the MF powdered diet (standard diet) for 6 weeks: standard diet control group, high-fat diet control group (induced dietary obesity) consisting of the standard diet and 20% lard, and mushroom chitosan groups consisting of the high-fat diet with mushroom chitosan added at 100, 500, 1,000, and 2,000 mg/kg body weight. On the final day of the experiment, mean body weight was 39.1 g in the high-fat control group and 36.3 g in the 2,000 mg/kg mushroom chitosan group, compared to 35.8 g in the standard diet control group. In the mushroom chitosan groups, a dose-dependent suppression of weight gain and marked improvements in serum triglycerides, total cholesterol, LDL-cholesterol, and HDL-cholesterol were found. The mushroom chitosan groups showed fewer and smaller fat deposits in liver cells than the high-fat diet control group, and liver weight was significantly reduced. Glutamic oxaloacetic transaminase (GOT) and glutamate pyruvic transaminase (GPT), which are indices of the hepatic function, all showed dose-dependent improvement with mushroom chitosan administration. These results suggested that mushroom chitosan acts to suppress enlargement of the liver from fat deposition resulting from a high-fat diet and to restore hepatic function. The lipid content of feces showed a marked increase correlated with the mushroom chitosan dose. These findings suggest the potential use of mushroom chitosan as a functional food ingredient that contributes to the prevention or improvement of dietary obesity by inhibiting digestion and absorption of fats in the digestive tract and simultaneously promotes lipolysis in adipocytes.
[Mh] Termos MeSH primário: Quitosana/administração & dosagem
Quitosana/isolamento & purificação
Dieta Hiperlipídica/efeitos adversos
Flammulina/química
Obesidade/prevenção & controle
Fitoterapia
[Mh] Termos MeSH secundário: Adipócitos/metabolismo
Administração Oral
Animais
Fármacos Antiobesidade
Quitosana/farmacologia
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Lipólise/efeitos dos fármacos
Masculino
Camundongos Endogâmicos ICR
Hepatopatia Gordurosa não Alcoólica/prevenção & controle
Obesidade/etiologia
Obesidade/metabolismo
Ganho de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 9012-76-4 (Chitosan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.5650/jos.ess17159


  3 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441973
[Au] Autor:Gong F; Niu J; Pei X
[Ti] Título:Clinical effects of dressing on patients with I-II phase pressure sores.
[So] Source:Pharmazie;71(11):665-669, 2016 Nov 02.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Angelica dahurica is a well-known traditional Chinese Medicine (TCM), while little information is available about its effects on pressure sores. We aimed to investigate the clinical effect of Angelica dahurica on patients with I-II phase pressure sores, as well as the underlying mechanism. METHODS: Patients (n = 98) with phase I and phase II pressure sores were enrolled and randomly assigned to control and treated groups. In addition to holistic nursing, patients in the control group received compound clotrimazole cream, while patients in the treated group received continuous 4 weeks of external application of Angelica dahurica dressing. Therapeutic effect was recorded, along with the levels of interleukin-8 (IL-8), epidermal growth factor (EGF), transforming growth factor (TGF)-ß, and vascular endothelial growth factor (VEGF). Besides, HaCaT cells were cultured with different concentrations of Angelica dahurica, and then cell viability, clone formation numbers, cell cycle, and levels of cyclin D1 and cyclin-dependent kinase (CDK) 2 were determined. RESULTS: The total effective rate in the treated group was significantly higher than in the control group. Levels of IL-8, EGF, TGF-ß, and VEGF were statistically increased by Angelica dahurica. In addition, the cell viability and clone formation numbers were significantly upregulated by Angelica dahurica in a dose-dependent manner. Also, the percentage of cells in G0/G1 phase, and levels of cyclin D1 and CDK2 were significantly elevated. CONCLUSION: Our results suggest that Angelica dahurica may provide an effective clinical treatment for I-II phase pressure sores.
[Mh] Termos MeSH primário: Angelica/química
Lesão por Pressão/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Bandagens
Ciclo Celular/efeitos dos fármacos
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Citocinas/biossíntese
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Peptídeos e Proteínas de Sinalização Intercelular/biossíntese
Masculino
Meia-Idade
Pomadas
Fitoterapia
Lesão por Pressão/metabolismo
Lesão por Pressão/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cytokines); 0 (Intercellular Signaling Peptides and Proteins); 0 (Ointments)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6704


  4 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465597
[Au] Autor:Yang F; Zou J; Ge L; Tian J; Lee MS; Jun JH; Zhang J
[Ad] Endereço:Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin.
[Ti] Título:Chinese herbal injections for heart failure: A protocol for systematic review and network meta-analyses.
[So] Source:Medicine (Baltimore);97(8):e9973, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chinese herbal injections (CHIs) are commonly used for the treatment of heart failure in China. Due to the variety of CHIs used in clinic, selecting a suitable CHI for patients with heart failure is vital. This study aims to assess and compare the effect of different CHIs for heart failure using network meta-analysis (NMA). METHODS: Six electronic databases, including PubMed, the Cochrane Central Register of Controlled Trials, Embase, China National Knowledge Infrastructure, Wanfang, and Chinese Biomedical Literature Database will be search from inception to January 2018. Randomized controlled trial (RCT) comparing CHI with another CHI will be included. The primary outcome will be changes in heart function classification and left ventricular ejection fraction. Risk of bias assessment of the included RCTs will be conducted according to the Cochrane Handbook 5.1.0. A Bayesian NMA will be performed using WinBUGS 14 software and the result figures will be generated using Stata 13 software. GRADE will be used to explore the quality of evidence. RESULTS: The results of this NMA will be published in a peer-reviewed journal. CONCLUSION: Our study will generate evidence of CHIs for patients with heart failure and provide suggestions for Chinese medicine clinical practice or guideline. ETHICS AND DISSEMINATION: Ethics approval and patient consent are not required because this study is an NMA based solely on the published literature. The results of this NMA will be submitted to a peer-reviewed journal. PROTOCOL REGISTRATION NUMBER: PROSPERO CRD 42018086740.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/administração & dosagem
Insuficiência Cardíaca/tratamento farmacológico
Fitoterapia/métodos
[Mh] Termos MeSH secundário: Teorema de Bayes
Protocolos Clínicos
Seres Humanos
Injeções
Metanálise em Rede
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009973


  5 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29425008
[Au] Autor:Momot TV; Kushnerova NF; Rakhmanin YA
[Ti] Título:[Prevention of deteriorations of blood biochemical indices in experimental stress in rats].
[So] Source:Gig Sanit;95(7):678-81, 2016.
[Is] ISSN:0016-9900
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Results of the research of the impact of extract from the byproducts of guelder-rose, containing a complexflavonoides (65% of dry weight), in the conditions of experimental a stress (vertical fixing of rats by a dorsal cervicalfold for 22 o'clock) are presented. The impact of a stress was shown to be followed by the gain in mass of adrenal glands by 42%. In blood serum there were noted marked hypertriglyceridemia, hypercholesterolemia, increased superoxide dismutase activity, decline in the number of reduced glutathione and anti-radical activity, the gain in lisofractions of phospholipids, decrease of phosphatidylcholine, phosphatidylethanolamine, cholesterol esters. Administration of the extract from the byproducts of guelder rose crushing promoted the normalization of indices of mass of adrenal glands and lipid metabolism in blood serum, was more effective, than a reference stress protector "Extract eleuterokokka®". The introduction of eleuterococcus was followed by the persistent both elevated level of cholesterol, free fatty acids, lisofraction of phospholipidsand low level offatty acids esters, cholesterol esters and a diphosphatidilglicerin. Byproducts of guelder-rose were shown to represent a perspective view of raw materials for the producing of stress protective preparations.
[Mh] Termos MeSH primário: Glândulas Suprarrenais/patologia
Síndrome de Adaptação Geral
Metabolismo dos Lipídeos/efeitos dos fármacos
Fitoterapia/métodos
Extratos Vegetais/farmacologia
Viburnum
[Mh] Termos MeSH secundário: Animais
Colesterol/sangue
Síndrome de Adaptação Geral/sangue
Síndrome de Adaptação Geral/etiologia
Síndrome de Adaptação Geral/terapia
Tamanho do Órgão
Ratos
Estresse Fisiológico/efeitos dos fármacos
Estresse Fisiológico/fisiologia
Superóxido Dismutase/metabolismo
Resultado do Tratamento
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol); EC 1.15.1.1 (Superoxide Dismutase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  6 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29385990
[Au] Autor:Schoendorfer N; Sharp N; Seipel T; Schauss AG; Ahuja KDK
[Ad] Endereço:School of Medicine, University of Queensland, Herston, Australia.
[Ti] Título:Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial.
[So] Source:BMC Complement Altern Med;18(1):42, 2018 Jan 31.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Storage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence (UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been documented both empirically and in emerging scientific research to have varying benefits in reducing bladder symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™ (Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI. METHODS: Efficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis included mixed effects ordered logistic regression with post hoc Holm's test to account for repeated measures, and included an intention-to-treat analysis. RESULTS: One hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment (mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night). Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower (all p < 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment. CONCLUSIONS: The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and consideration by clinicians. TRIAL REGISTRATION: NCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced).
[Mh] Termos MeSH primário: Extratos Vegetais/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
Incontinência Urinária/tratamento farmacológico
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Capparaceae
Equisetum
Feminino
Seres Humanos
Lindera
Masculino
Registros Médicos
Meia-Idade
Fitoterapia
Extratos Vegetais/farmacologia
Micção/efeitos dos fármacos
Agentes Urológicos/farmacologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Plant Extracts); 0 (Urological Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-018-2101-4


  7 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386000
[Au] Autor:Wang KH; Wu JR; Zhang D; Duan XJ; Ni MW
[Ad] Endereço:Department of Clinical Pharmacology of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China.
[Ti] Título:Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis.
[So] Source:BMC Complement Altern Med;18(1):41, 2018 Jan 31.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: On account of deterioration of chronic heart failure (CHF) and extensive exploration of Chinese herbal injections (CHIs), we performed a network meta-analysis to investigate the efficacy of CHIs (Huangqi injection, Shenfu injection, Shengmai injection, Shenmai injection, Shenqi Fuzheng injection, Yiqifumai injection) on the basis of western medicine (WM) treatment in CHF. METHODS: Literature search was conducted in Embase, the Cochrane Library, Pubmed, Chinese Biological Medicine Database, China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database from inception to June 12nd 2017, and study selection was abided by a prior eligible criteria. RESULTS: Ultimately, a total of 113 randomized controlled trials (RCTs) were enrolled. The clinical data of the effective clinical rate, left ventricular ejection fraction, cardiac output and others outcomes was estimated by Stata software and Winbugs software. Risk of bias was assessed by Cochrane Collaboration's tools. Integrating the each outcome's results, a combination of Shengmai injection/Shenmai injection and WM obtain a first rank in most outcomes, particularly primary outcomes. CONCLUSIONS: In conclusion, on the basis of WM, Shengmai injection or Shenmai injection may be a perforable treatment in CHF. In terms of insufficient of this study, more high quality RCTs needed to implement to support our conclusions.
[Mh] Termos MeSH primário: Doença Crônica/tratamento farmacológico
Medicamentos de Ervas Chinesas/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
[Mh] Termos MeSH secundário: Medicamentos de Ervas Chinesas/administração & dosagem
Seres Humanos
Injeções
Fitoterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-018-2090-3


  8 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29341893
[Au] Autor:Khan H; Amin S; Patel S
[Ad] Endereço:Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan. Electronic address: hkdr2006@gmail.com.
[Ti] Título:Targeting BDNF modulation by plant glycosides as a novel therapeutic strategy in the treatment of depression.
[So] Source:Life Sci;196:18-27, 2018 Mar 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Current therapies in clinical practice face strong criticism regarding their efficacy, and side effects, which forced the neuro-researchers to discover novel agents with different mechanistic insights. Glycosides are naturally-occurring plant secondary metabolites with significant medicinal potential and clinical scope as antidepressant. The aim of this review is to focus on the antidepressant effects of glycosides in preclinical studies, with an emphasis on the possible mechanisms. The literature search revealed that only a few phytoglycosides have been evaluated for their relevance in depression alleviation. Through preclinical tests, it has come forth that the efficacy is mediated by the modulation of brain-derived neurotrophic factor (BDFN) in the hippocampus, that is known for promoting synaptic efficacy, neuronal connectivity and neuroplasticity. Thus, attempting the upregulation of BDNF expression by plant glycosides can be a novel therapeutic strategy for the treatment of depression. The outcome of this review can stimulate neuroscientists to evaluate plant-derived glycosides for the treatment of depression, as these structurally-complex and diverse molecules, might usher in a new paradigm in the treatment of depression, with a better efficacy and tolerability.
[Mh] Termos MeSH primário: Antidepressivos/uso terapêutico
Fator Neurotrófico Derivado do Encéfalo/efeitos dos fármacos
Depressão/tratamento farmacológico
Depressão/metabolismo
Glicosídeos/uso terapêutico
Fitoterapia
Plantas/química
[Mh] Termos MeSH secundário: Animais
Antidepressivos/efeitos adversos
Antidepressivos/farmacologia
Fator Neurotrófico Derivado do Encéfalo/metabolismo
Glicosídeos/efeitos adversos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Brain-Derived Neurotrophic Factor); 0 (Glycosides); 0 (brain-derived neurotrophic factor, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE


  9 / 35275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471166
[Au] Autor:Batarseh YS; Bharate SS; Kumar V; Kumar A; Vishwakarma RA; Bharate SB; Kaddoumi A
[Ad] Endereço:Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe , Monroe, Louisiana 71201, United States.
[Ti] Título:Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid ß Load and Related Toxicity in 5XFAD Mice.
[So] Source:ACS Chem Neurosci;8(8):1756-1766, 2017 08 16.
[Is] ISSN:1948-7193
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Crocus sativus, commonly known as saffron or Kesar, is used in Ayurveda and other folk medicines for various purposes as an aphrodisiac, antispasmodic, and expectorant. Previous evidence suggested that Crocus sativus is linked to improving cognitive function in Alzheimer's disease (AD) patients. The aim of this study was to in vitro and in vivo investigate the mechanism(s) by which Crocus sativus exerts its positive effect against AD. The effect of Crocus sativus extract on Aß load and related toxicity was evaluated. In vitro results showed that Crocus sativus extract increases the tightness of a cell-based blood-brain barrier (BBB) model and enhances transport of Aß. Further in vivo studies confirmed the effect of Crocus sativus extract (50 mg/kg/day, added to mice diet) on the BBB tightness and function that was associated with reduced Aß load and related pathological changes in 5XFAD mice used as an AD model. Reduced Aß load could be explained, at least in part, by Crocus sativus extract effect to enhance Aß clearance pathways including BBB clearance, enzymatic degradation and ApoE clearance pathway. Furthermore, Crocus sativus extract upregulated synaptic proteins and reduced neuroinflammation associated with Aß pathology in the brains of 5XFAD mice. Crocin, a major active constituent of Crocus sativus and known for its antioxidant and anti-inflammatory effect, was also tested separately in vivo in 5XFAD mice. Crocin (10 mg/kg/day) was able to reduce Aß load but to a lesser extent when compared to Crocus sativus extract. Collectively, findings from this study support the positive effect of Crocus sativus against AD by reducing Aß pathological manifestations.
[Mh] Termos MeSH primário: Doença de Alzheimer/tratamento farmacológico
Peptídeos beta-Amiloides/efeitos dos fármacos
Barreira Hematoencefálica/efeitos dos fármacos
Crocus
Fármacos Neuroprotetores/farmacologia
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Administração Oral
Doença de Alzheimer/metabolismo
Doença de Alzheimer/patologia
Peptídeos beta-Amiloides/metabolismo
Peptídeos beta-Amiloides/toxicidade
Animais
Anti-Inflamatórios não Esteroides/química
Anti-Inflamatórios não Esteroides/farmacologia
Barreira Hematoencefálica/metabolismo
Barreira Hematoencefálica/patologia
Linhagem Celular
Crocus/química
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Células Endoteliais/efeitos dos fármacos
Células Endoteliais/metabolismo
Células Endoteliais/patologia
Inflamação/tratamento farmacológico
Inflamação/metabolismo
Inflamação/patologia
Masculino
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Microvasos/efeitos dos fármacos
Microvasos/metabolismo
Microvasos/patologia
Fármacos Neuroprotetores/química
Fitoterapia
Extratos Vegetais/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Neuroprotective Agents); 0 (Plant Extracts)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1021/acschemneuro.7b00101


  10 / 35275 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29206653
[Au] Autor:Kang JM; Lin S
[Ad] Endereço:Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA.
[Ti] Título:Ginkgo biloba and its potential role in glaucoma.
[So] Source:Curr Opin Ophthalmol;29(2):116-120, 2018 Mar.
[Is] ISSN:1531-7021
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: This study will review the research on the effect of ginkgo biloba extract (GBE) on patients with glaucoma. RECENT FINDINGS: GBE appears to increase ocular blood flow in those with glaucoma. However, data on visual field outcomes are inconclusive. SUMMARY: GBE has been shown to have antioxidant and vascular effects, making it potentially effective in treating glaucoma. Published data are limited but show an increase in ocular blood flow after GBE administration. Conclusive evidence is lacking regarding the effect of GBE on clinical outcomes in glaucoma patients such as visual field performance.
[Mh] Termos MeSH primário: Terapias Complementares
Glaucoma/tratamento farmacológico
Pressão Intraocular/efeitos dos fármacos
Fitoterapia/métodos
Extratos Vegetais/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Ginkgo biloba/química
Glaucoma/fisiopatologia
Seres Humanos
Pressão Intraocular/fisiologia
Fluxo Sanguíneo Regional/fisiologia
Campos Visuais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Plant Extracts); 19FUJ2C58T (Ginkgo biloba extract)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1097/ICU.0000000000000459



página 1 de 3528 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde